NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis $0.36 +0.01 (+3.86%) Closing price 04:00 PM EasternExtended Trading$0.36 +0.00 (+1.28%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Senti Biosciences Stock (NASDAQ:SNTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Senti Biosciences alerts:Sign Up Key Stats Today's Range$0.34▼$0.3850-Day Range$0.35▼$1.1152-Week Range$0.34▼$2.88Volume132,890 shsAverage Volume221,555 shsMarket Capitalization$11.23 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases. Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release. These platforms support a diverse pipeline of preclinical cell therapy programs targeting solid tumors, hematologic malignancies and autoimmune disorders. Founded in 2018 and headquartered in Cambridge, Massachusetts, Senti Biosciences completed its initial public offering in June 2021 and is listed on the Nasdaq exchange. The company collaborates with academic and industry partners to advance its research and expand its proprietary platform capabilities. Senti is led by a management team combining expertise in synthetic biology, immunology and biotechnology development. The leadership team includes seasoned industry executives and academic scientists committed to translating circuit-based cell therapies into clinical applications worldwide.AI Generated. May Contain Errors. Read More Senti Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreSNTI MarketRank™: Senti Biosciences scored higher than 57% of companies evaluated by MarketBeat, and ranked 468th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingSenti Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSenti Biosciences has a consensus price target of $10.00, representing about 2,674.7% upside from its current price of $0.36.Amount of Analyst CoverageSenti Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Senti Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Senti Biosciences are expected to grow in the coming year, from ($1.53) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Senti Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.01% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 1.71, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.94 News SentimentSenti Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Senti Biosciences this week, compared to 2 articles on an average week.Search Interest3 people have searched for SNTI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.12% of the stock of Senti Biosciences is held by insiders.Percentage Held by Institutions25.70% of the stock of Senti Biosciences is held by institutions.Read more about Senti Biosciences' insider trading history. Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNTI Stock News HeadlinesSenti Biosciences (SNTI) Projected to Announce Earnings on ThursdayJuly 30 at 3:41 AM | americanbankingnews.comSenti Biosciences (NASDAQ:SNTI) Stock Price Down 3.2% - What's Next?July 24, 2026 | americanbankingnews.comSpaceX just minted 4,400 millionairesSpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times. Peter Thiel, SpaceX's first major backer, just placed a $1 billion bet on a private defense company - and Dr. Mark Skousen believes an IPO announcement could be imminent. Skousen predicted the SpaceX IPO filing a week before it happened and is now sharing the ticker behind Thiel's next move.July 30 at 1:00 AM | The Oxford Club (Ad)Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...July 15, 2026 | markets.businessinsider.comSenti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology PlatformJuly 15, 2026 | globenewswire.comSenti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note StructureMay 16, 2026 | tipranks.comSenti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...May 14, 2026 | markets.businessinsider.comSenti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid LeukemiaMay 14, 2026 | quiverquant.comQSee More Headlines SNTI Stock Analysis - Frequently Asked Questions How have SNTI shares performed this year? Senti Biosciences' stock was trading at $1.04 on January 1st, 2026. Since then, SNTI shares have decreased by 65.3% and is now trading at $0.3604. How were Senti Biosciences' earnings last quarter? Senti Biosciences, Inc. (NASDAQ:SNTI) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.22. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. When did Senti Biosciences' stock split? Senti Biosciences's stock reverse split on the morning of Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Senti Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI). Company Calendar Last Earnings5/14/2026Today7/30/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (13m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 SNTI's financial health is in the Red zone, according to TradeSmith. SNTI has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNTI CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees4Year Founded2016Price Target and Rating Average Price Target for Senti Biosciences$10.00 High Price Target$12.00 Low Price Target$6.00 Potential Upside/Downside+2,674.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.44 million Net MarginsN/A Pretax Margin-135,649.98% Return on Equity-532.05% Return on Assets-103.35% Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio1.04 Sales & Book Value Annual Sales$20 thousand Price / Sales561.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book2.00Miscellaneous Outstanding Shares31,150,000Free Float30,173,000Market Cap$11.23 million OptionableNot Optionable Beta2.04 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:SNTI) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe oil crisis is spreading faster than you thinkTanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...Golden Portfolio | SponsoredWhile the world panicked, these investors got paidSince Feb 28, the S&P 500 has slid 4.1% amid war fears and oil spikes to $117. Patriot Income Plan (P.I.P.) pa...Freedom Financial | SponsoredSell SpaceX Now. Buy This Instead.Rob Spivey traveled to SpaceX's Starbase, Texas headquarters to uncover what Wall Street missed in the company...Altimetry | SponsoredEye-opening video on new space economyGoldman Sachs is calling it the Second Space Age, with projections of up to 10 trillion dollars flowing into t...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
